Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).
Chiara Ciccarese(Agostino Gemelli University Polyclinic), Roberto Iacovelli(Agostino Gemelli University Polyclinic), Sebastiano Buti(University of Parma), Fabio Calabrò(Carlo Forlanini Hospital), Davide Bimbatti(Istituto Oncologico Veneto), Luca Galli(University of Pisa), Giuseppa Scandurra, Cinzia Baldessari(Azienda Ospedaliero-Universitaria di Modena), Elena Verzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Stanislaw Milella(University of Verona), Carlo Cattrini(Azienda Ospedaliera Ospedale Maggiore), Gaetano Facchini(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Sarah Scagliarini(Ospedale Antonio Cardarelli), Cristina Masini(Ospedale Santa Maria), Giuseppe Fornarini(Ospedale Policlinico San Martino), Franco Nolè(European Institute of Oncology), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alfredo Berruti(Surgical Specialties (Canada)), Maria Olga Giganti(Istituti Ospitalieri di Cremona), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi)
Cited by 0
Related Papers
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268